In a report released on February 16, Daina Graybosch from Leerink Partners maintained a Buy rating on Nkarta (NKTX – Research Report). The company’s shares closed last Friday at $10.84.
According to TipRanks, Graybosch is an analyst with an average return of -3.1% and a 37.31% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and BioNTech SE.
Nkarta has an analyst consensus of Strong Buy, with a price target consensus of $14.25.
See Insiders’ Hot Stocks on TipRanks >>
Based on Nkarta’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $25.65 million. In comparison, last year the company had a GAAP net loss of $28.35 million
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nkarta (NKTX) Company Description:
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
Read More on NKTX:
